The Diagnostic Value of Anti-Mullerian Hormone Marker in Predicting Response to Treatment of Infertility in Patients with Polycystic Ovary Syndrome

Document Type : Original Article (s)

Authors

1 Professor, Department of Genecology and Obstetrics, Shahid Beheshti Hospital Infertility Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, School of Medicine AND Students Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: This study aimed to evaluate the diagnostic value of anti-Mullerian hormone (AMH) marker in predicting response to treatment of infertility in patients with polycystic ovary syndrome (PCOS).Methods: This study was conducted on 80 patients with PCOS who were candidates for infertility treatment. In all patients, the serum levels of AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone and estradiol were measured in the 3rd day of menstrual cycle; then were treated using clomiphene. For the patient who responded to clomiphene, human menopausal gonadotropin (HMG) was added. Then, in the patient with follicle of size of 17 mm, human corionic gonadotropin (HCG) was administered followed by intercourse after 36 hours. After 14 days from HCG injection, βhCG was measured. In patients with positive βhCG, transvaginal sonography was done after 2 weeks. The relationship between serum level of AMH and pregnancy rate were assessed. P value of more than 0.05 was concedered as significant.Findings: Cut-of-point for AMH level according to presence or absence of pregnancy was 4.85 ng/ml and it was not statistically significant (P = 0.079).Conclusion: This study shows that the serum level of AMH is not an appropriate predictor of responsing to treatment with clomiphene + gonadotropin in weman with PCOS.

Keywords

References

  1. Hwang YI, Sung NY, Koo HS, Cha SH, Park CW, Kim JY, et al. Can high serum anti-Mullerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients? Clin Exp Reprod Med 2013; 40(3): 135-40.
  2. Saikumar P, Selvi VK, Prabhu K, Venkatesh P, Krishna P. Anti mullerian hormone: a potential marker for recruited non growing follicle of ovarian pool in women with polycystic ovarian syndrome. J Clin Diagn Res 2013; 7(9): 1866-9.
  3. Amer SA, Mahran A, Abdelmaged A, El-Adawy AR, Eissa MK, Shaw RW. The influence of circulating anti-Mullerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study. Reprod Biol Endocrinol 2013; 11: 115.
  4. Aleyasin A, Aghahoseini M, Mokhtar S, Fallahi P. Anti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients. Acta Med Iran 2011; 49(11): 715-20.
  5. Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E. Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age. Akush Ginekol (Sofiia) 2013; 52(Suppl 1): 16-23.
  6. Johanna S. Polycystic ovary syndrome ovarian pathophysiology and consequences after the menopause [Thesis]. Gothenburg, Sweden: Institute of clinical sciences at Sahlgerenska Academy, University of Gothenburg; 2011. p. 24-37.
  7. Sahmay S, Atakul N, Oncul M, Tuten A, Aydogan B, Seyisoglu H. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013; 170(1): 157-61.
  8. Kim JY, Yi G, Kim YR, Chung JY, Ahn JH, Uhm YK, et al. Association between serum anti-Mullerian hormone level and ovarian response to mild stimulation in normoovulatory women and anovulatory women with polycystic ovary syndrome. Clin Exp Reprod Med 2013; 40(2): 95-9.
  9. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008; 23(4): 952-7.
  10. La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG 2012; 119(10): 1171-9.
Journal of Isfahan Medical School
Volume 34, Issue 395 - Serial Number 395
July and August 2016
Pages 978-984

Files

History

  • Receive Date: 23 May 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics